Clinical trials: Stage 2 Hypertension
Pulmonary Hypertension
Sildenafil for Post-capillary Pulmonary Hypertension in Patients Undergoing Cardiac Surgery
Pulmonary hypertension increases the perioperative risk in patients undergoing cardiac surgery for valvular heart diseases, especially in patients with a long life mitral valve disease.
- Trial name
- SiPaHCS (NCT01481350)
- Testing
- sildenafil
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University of Turin, Italy
Hypertension, Acute Severe Hypertension
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.
- Conditions
- Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
- Trial name
- KARDINAL-ASH (NCT07511361)
- Testing
- Tonlamarsen
- Where
- 13 sites in United States
- Volunteers
- 140 people
- Sponsor
- Kardigan, Inc.
Essential Hypertension
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension
The primary objective of the study is to evaluate the safety and tolerability of single ascending doses of Vasomera (PB1046) administered subcutaneously in adult subjects with Stage 1 or Stage 2 essential hypertension.
- Trial name
- NCT01523067
- Testing
- Vasomera (PB1046), 0.9% Sodium Chloride
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Diabetes Mellitus, Type 2, Hypertension
Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)
MK-8835-042 (B1521004) is designed to assess the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729), in participants with type 2 diabetes and hypertension.
- Trial name
- NCT01096667
- Testing
- Ertugliflozin 1 mg, Ertugliflozin 5 mg, Ertugliflozin 25 mg
- Volunteers
- 194 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
Phase 3, placebo controlled, double-blind, randomized clinical study to determine safety, tolerability, and efficacy of pulsed, inhaled nitric oxide (iNO) versus placebo in symptomatic subjects with pulmonary arterial…
- Trial name
- INOvation-1 (NCT02725372)
- Testing
- Inhaled Nitric Oxide 75 mcg/kg IBW/hr
- Where
- 109 sites in United States, Australia and 16 more
- Volunteers
- 207 people
- Sponsor
- Bellerophon Pulse Technologies
Breast Cancer, Cardiovascular Complications
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving bevacizumab may help doctors learn more about changes that occur in DNA and identify biomarkers related to high blood pressure.
- Conditions
- Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01096381
- Testing
- laboratory biomarker analysis, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Open-Angle Glaucoma, Ocular Hypertension
A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)
The study objective is to compare IOP and safety outcomes based on plug placement (upper or lower puncta).
- Trial name
- NCT00821002
- Testing
- Latanoprost
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mati Therapeutics Inc.
Hypertension
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of Black stage II hypertensive patients (MSSBP ≥ 160 mmHg).
- Trial name
- NCT00353912
- Testing
- valsartan + amlodipine
- Where
- United States
- Volunteers
- 571 people
- Sponsor
- Novartis
Pulmonary Arterial Hypertension
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
This Phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study will compare the efficacy, safety, and tolerability of cicletanine hydrochloride (HCl) to placebo in subjects with PAH.
- Trial name
- NCT00832507
- Testing
- Cicletanine
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 162 people
- Sponsor
- Gilead Sciences
Hypertension
A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment
This study is a multi-center, open label, dose titration, exploratory study to evaluate efficacy and safety of CS-3150 in Japanese hypertensive patients with moderate renal impairment.
- Trial name
- NCT02448628
- Testing
- CS-3150
- Where
- Japan
- Volunteers
- 33 people
- Sponsor
- Daiichi Sankyo
Hypertension
A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension
The purpose of this study is to determine a safe and effective dose of ADX415 for the treatment of hypertension.
- Trial name
- NCT00779181
- Testing
- ADX415
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Addrenex Pharmaceuticals, Inc.
Hypertension
Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B
The purpose of this study is to evaluate a pharmacokinetic drug interaction and safety.
- Trial name
- NCT06618079
- Testing
- HUC2-565-A, HUC2-565-A and HUC2-565-B, HUC2-565-B, HUC2-565-A and HUC2-565-B
- Where
- South Korea
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Glaucoma Open-angle
Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution
This is a randomized trial comparing two elution doses of the Travoprost Intraocular implant to timolol ophthalmic solution.
- Trial name
- NCT02754596
- Testing
- Travoprost Intraocular Implant, high elution, Travoprost Intraocular Implant, low elution, Timolol Maleate Ophthalmic Solution, 0.5%
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Glaukos Corporation
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH.
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Trial name
- RENEU-PH (NCT07221513)
- Testing
- JK07
- Where
- United States
- Sponsor
- Salubris Biotherapeutics Inc
Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
- Trial name
- Re-PHIRE (NCT05737940)
- Testing
- AZD3427
- Where
- 60 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- AstraZeneca
Metabolic Syndrome
Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
Metabolic syndrome: aetiology, pathogenesis, diagnosis, clinical management and prognosis
- Trial name
- DRWMNTMS (NCT02503865)
- Testing
- Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin, "Analimentary detoxication"
- Where
- Kazakhstan
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Nazarbayev University
Hypertension, Diabetes
Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)
The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and…
- Conditions
- Hypertension, Diabetes, Proteinuria
- Trial name
- TANDEM (NCT00234871)
- Testing
- trandolapril/verapamil, Lotrel (amlodipine/benazepril)
- Volunteers
- 357 people
- Sponsor
- Abbott
Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.
- Conditions
- Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension (OHT)
- Trial name
- NCT06016972
- Testing
- Experimental: QLS-111 ophthalmic solution, (0.015%), Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Qlaris Bio, Inc.
Pulmonary Hypertension, Interstitial Lung Disease
A Study of Mosliciguat in PH-ILD
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
- Trial name
- PHocus (NCT06635850)
- Testing
- Mosliciguat, Dry Powder Inhaler
- Where
- 85 sites in United States, Argentina and 18 more
- Volunteers
- 135 people
- Sponsor
- Pulmovant, Inc.
Elevated LDL-C and High Cholesterol
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene.
- Trial name
- STX-1150-01 (NCT07428473)
- Testing
- STX-1150
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 64 people
- Sponsor
- Monash University